Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 10 de 10
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
7.
Vet Res Commun ; 30(6): 623-35, 2006 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-16838204

RESUMO

Beta-agonists have been shown to display anti-inflammatory properties in several experimental models. The aim of this study was to investigate the anti-inflammatory properties of clenbuterol (CB), administered either intravenously or by aerosol, in comparison with fluticasone propionate (FP) in recurrent airway obstruction (RAO)-susceptible horses. Eight horses, of which five were known to be susceptible to RAO, underwent an inhalation challenge with Aspergillus fumigatus (AF) antigen and were treated with CB intravenously, CB by aerosol, or FP by aerosol. Twenty-four hours after the challenge, bronchoalveolar lavage was performed, the total and differential cell counts were assessed, and cytokines were measured in isolated alveolar macrophages. After challenge with AF, RAO-susceptible horses showed an increase in total cell count, based on an increase in macrophages and lymphocytes, which was inhibited by treatment with intravenous CB, aerosolized CB and aerosolized FP. Neutrophil ratios were decreased when treated with aerosolized CB and FP. Expression of interleukin (IL)-1beta and IL -8 was significantly increased after AF challenge . Interleukin -1beta was significantly decreased following treatment with intravenous CB, aerosolized CB and aerosolized FP, whereas only FP decreased the expression of IL-8. These data suggest that the anti-inflammatory property of CB provide new opportunities in the therapeutic intervention of early inflammation in RAO.


Assuntos
Androstadienos/uso terapêutico , Antígenos de Fungos/uso terapêutico , Broncodilatadores/uso terapêutico , Clembuterol/uso terapêutico , Doenças dos Cavalos/tratamento farmacológico , Pneumopatias Obstrutivas/veterinária , Administração por Inalação , Androstadienos/administração & dosagem , Animais , Aspergillus fumigatus/imunologia , Aspergillus fumigatus/patogenicidade , Líquido da Lavagem Broncoalveolar/citologia , Broncodilatadores/administração & dosagem , Clembuterol/administração & dosagem , Citocinas/metabolismo , Feminino , Fluticasona , Doenças dos Cavalos/imunologia , Cavalos , Injeções Intravenosas/veterinária , Pneumopatias Obstrutivas/tratamento farmacológico , Pneumopatias Obstrutivas/imunologia , Macrófagos Alveolares/metabolismo , Distribuição Aleatória , Resultado do Tratamento
9.
Vet Rec ; 155(12): 361-4, 2004 Sep 18.
Artigo em Inglês | MEDLINE | ID: mdl-15493604

RESUMO

Healthy horses received aerosolised, intranasal or oral doses of 3 mg of fluticasone propionate evenly divided over morning and evening treatments for seven days. The bioavailability of the drug was determined in terms of the suppression of the endogenous cortisol concentrations in the horses during the period of treatment. The horses which received the aerosolised drug had significantly lower concentrations of endogenous cortisol on days 5 and 8 than the horses which received aerosolised placebo. The horses which received nasal and oral doses of fluticasone propionate showed no significant changes in their endogenous cortisol concentrations.


Assuntos
Obstrução das Vias Respiratórias/veterinária , Androstadienos/farmacocinética , Anti-Inflamatórios/farmacocinética , Doenças dos Cavalos/tratamento farmacológico , Administração por Inalação , Administração Intranasal , Administração Oral , Obstrução das Vias Respiratórias/tratamento farmacológico , Androstadienos/uso terapêutico , Animais , Anti-Inflamatórios/uso terapêutico , Área Sob a Curva , Disponibilidade Biológica , Estudos Cross-Over , Feminino , Fluticasona , Cavalos , Hidrocortisona/sangue , Distribuição Aleatória , Resultado do Tratamento
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...